Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Purple Biotech (PPBT) Enterprise Value (2016 - 2026)

Purple Biotech has reported Enterprise Value over the past 7 years, most recently at -$15.3 million for Q4 2022.

  • Quarterly Enterprise Value rose 67.45% to -$15.3 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$15.3 million through Dec 2022, up 67.45% year-over-year, with the annual reading at -$15.3 million for FY2022, 67.69% up from the prior year.
  • Enterprise Value was -$15.3 million for Q4 2022 at Purple Biotech, up from -$32.9 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$4.4 million in Q2 2020 and troughed at -$57.4 million in Q4 2020.
  • The 5-year median for Enterprise Value is -$32.9 million (2022), against an average of -$29.4 million.
  • Year-over-year, Enterprise Value plummeted 1000.93% in 2021 and then surged 67.45% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$6.7 million in 2018, then grew by 4.47% to -$6.4 million in 2019, then crashed by 799.64% to -$57.4 million in 2020, then increased by 18.32% to -$46.9 million in 2021, then soared by 67.45% to -$15.3 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Enterprise Value are -$15.3 million (Q4 2022), -$32.9 million (Q3 2022), and -$32.9 million (Q2 2022).